Masked polycythaemia vera is genetically intermediate between JAK2V617F mutated essential thrombocythaemia and overt polycythaemia vera.

about

Masked polycythaemia vera is genetically intermediate between JAK2V617F mutated essential thrombocythaemia and overt polycythaemia vera.

Item

http://www.wikidata.org/entity/Q41085322

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Masked polycythaemia vera is g ...... and overt polycythaemia vera.

@en

type

Item

label

Masked polycythaemia vera is g ...... and overt polycythaemia vera.

@en

prefLabel

Masked polycythaemia vera is g ...... and overt polycythaemia vera.

@en

P1476

Masked polycythaemia vera is g ...... a and overt polycythaemia vera

@en

P2093

D A Casolari

http://www.w3.org/2001/XMLSchema#string

I S Tiong

http://www.w3.org/2001/XMLSchema#string

K Ambler

http://www.w3.org/2001/XMLSchema#string

M J M Van Velzen

http://www.w3.org/2001/XMLSchema#string

R J D'Andrea

http://www.w3.org/2001/XMLSchema#string

T Nguyen

http://www.w3.org/2001/XMLSchema#string

P2860

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.

TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.

Effect of mutation order on myeloproliferative neoplasms.

JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone.

Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.

Masked polycythemia vera (mPV): results of an international study.

Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes.

Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis.

P2888

bcj.2016.70

P304

e459

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BCJ.2016.70

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

David Ross

P577

2016-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1008178142

http://www.w3.org/2001/XMLSchema#string

P698

27540717

http://www.w3.org/2001/XMLSchema#string

P932

5022181

http://www.w3.org/2001/XMLSchema#string